iThriveMD review

iThriveMD publishes molecule-specific prices and describes baseline testing before treatment. Sermorelin is $249 monthly; prepaid terms lower the displayed equivalent but require the full term. Standalone TRT is $199 monthly, while TRT with enclomiphene is $289 monthly. The 90-day $79 member add-ons require another weight-loss or hormone plan, and the site’s shipping and return documents disagree.

iThriveMD runs California clinics, a Scottsdale location page and telehealth advertised for California and Arizona. Its menu includes sermorelin, NAD⁺ injections and wafers, GHK-Cu cream, PT-141, glutathione and testosterone. Standalone TRT is listed at $199 monthly; the separate TRT-with-enclomiphene choice is $289 monthly. NAD⁺ injections do not ship to Arizona, while NAD⁺ wafers may ship to Arizona and California.

Lab-driven and clinic-anchored, which is the substance of what you are buying. The practice describes a three-step method — measure, personalize, optimize — and states under the first step that there is in-depth diagnostic testing and baseline labs before any plan begins. For sermorelin that matters concretely: an IGF-1 baseline is the obvious thing to want before starting a growth-hormone secretagogue. Initial consultations are free, and having physical clinics means the option of being seen in person rather than posting a vial. Most of the named clinicians are naturopathic doctors rather than MDs, so ask who will actually prescribe. The commercial structure is the part to read carefully. Membership works as an unlock — the site's own framing is that starting one plan opens the whole menu — so the low member figures against each peptide are conditional on already being enrolled in a weight-loss or hormone program, and they run for 90 days. The member page offers free two-day shipping, while the shipping policy lists $9 ground delivery; ask which applies to the selected order. The gaps are sourcing and geography: the site shows a LegitScript seal and says its medications are dispensed by a LegitScript-certified pharmacy, but it does not name that pharmacy, and telehealth is limited to two states, which rules out most readers arriving at this page. Whether labs are billed inside or outside the quoted figures is not spelled out on the pricing pages.

Sermorelin is $249 billed and shipped monthly; three-, six- and twelve-month plans display $224.10, $211.65 and $199.20 per month but bill the full term upfront. NAD⁺ injection is $249 every 28 days, or $211.65, $161.85 and $124.50 per 28-day shipment on prepaid 12-, 24- and 48-week terms. Wafers are $100 monthly or $90, $85 and $80 monthly equivalent on three-, six- and twelve-month prepay. Standalone TRT is $199 monthly, with $179.10, $169.15 and $159.20 monthly equivalents on prepaid terms; TRT with enclomiphene is $289 monthly, with $260.10, $245.65 and $231.20 prepaid equivalents. A separate $79 member add-on rate lasts 90 days after starting a qualifying plan. The site lists a $499 diagnostic panel but does not establish whether required baseline labs are in each therapy price. The member page promises free two-day shipping while the shipping policy lists $9 FedEx ground; its return policy says final sale while generic terms describe a return process. Obtain order-specific terms in writing.

Compounded; not FDA-approved. Prescription required only if a licensed provider finds it appropriate. The compounding pharmacy is not named — only described as LegitScript-certified — and compounded sterile products are not reviewed by the FDA for purity and potency the way approved drugs are. On the evidence, the breadth of this menu is exactly why it should not be read as one longevity offer. Sermorelin acts on the growth-hormone axis, a real and well-described mechanism whose long-term human outcome data stays thin, with no controlled trial demonstrating the body-composition or recovery results it is marketed for. NAD⁺ by injection or wafer has no controlled human outcome trials at all; the oral precursors NR and NMN are the studied forms and raise blood NAD⁺, a biomarker rather than a benefit. Injectable glutathione and topical GHK-Cu have essentially no controlled human outcome evidence for the detox and skin-renewal claims attached to them. PT-141, or bremelanotide, is the outlier in the other direction — it has genuine human trial evidence and an approved product for hypoactive sexual desire disorder in premenopausal women, though a compounded version is not the approved product and the approval does not extend to general use. On the hormone side, testosterone therapy has a real evidence base together with real monitoring requirements and fertility suppression, and enclomiphene is offered here as part of the same protocol. Individual results vary.